Thursday 23rd June 2022, 1pm - 5.30pm
The Babraham Investor Conference 2021 (BIC) is a must attend event for investors focusing on early-stage and scale-up life science and med-tech companies.
The conference is a hybrid event, with options to attend in-person or online. Those attending virtually will have interactive opportunities to ask questions and participate in audience opinion polls. For those attending in-person, the conference will begin with a networking lunch in the Cambridge Building, 1pm – 2pm.
Venue: The Cambridge Building, Babraham Research Campus, Babraham CB22 3AT
Programme:
1 – 2pm: Networking lunch
2pm – 3.30pm: Key note presentation, scale up company presentations, Accelerate@Babraham company presentations.
Coffee Break
4pm – 5.30pm: Accelerate@Babraham competition, pitching for a place on the 2022 programme.
Sir Harpal is the President of GRAIL Europe and leads GRAIL’s biopharma business globally. Prior to GRAIL, he was Senior Vice President and Head of Innovation EMEA at Johnson & Johnson. Before joining J&J, Sir Harpal spent more than 15 years with Cancer Research UK and served as the organisation’s Chief Executive Officer from April 2007 until June 2018. Prior to this, he was Chief Operating Officer & Executive Director of Development at CRUK and served as Chief Executive of Cancer Research Technology (a subsidiary of CRUK). Before CRUK, he worked with McKinsey & Co, and was CEO of The Papworth Trust and Nexan Group.
Sir Harpal received a first-class Masters in Chemical Engineering from the University of Cambridge, and an MBA as a Baker Scholar from Harvard Business School. He has been awarded Honorary Doctorates from the Universities of Manchester, Newcastle, and Glasgow, and the Institute of Cancer Research, and he is an Honorary Fellow of the Academy of Medical Sciences, Royal College of Radiologists, Association of Cancer Physicians (UK) and St John’s College, University of Cambridge. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research. He is a Board Member of Our Future Health and is a member of the Oversight Committee of the Covid-19 National Core Studies.
Typically, presenting companies will be seeking funding of between £250K to £20M. Presenting slots of 10 minutes each (including Q&A) are available. There is also the opportunity to have an exhibition stand in the Cambridge Building. There is no charge to apply, however, we do request a fee of £100+VAT from each company successful in securing a slot to present. To apply, please click the link below and you will receive a non-confidential investment profile to complete. All applications are reviewed by our panel and successful companies will be contacted via email.
Taylor Vinters is a legal and advisory business designed to support the organisations that are driving the innovation economy.
Starting something new is hard – particularly within the fast-moving life science sector. Step forward Accelerate@Babraham, the Babraham Research Campus’ bio-incubator, founded out of a desire to support and nurture early-stage ventures; bringing to bear an unrivalled network of experts, mentors and investors to equip young enterprises with the skills, confidence and network connections to enable success. Since launching in 2018, we have supported 20 fledgling life-science companies. Each cohort brings with it a diverse set of skills, expertise and experience, but they all share a deep passion for their science or technology and a desire to make a difference to the lives of tomorrow’s patients. Applications for the 2022/23 cohort are now OPEN, click below to find out more and apply!
To read about the 2021 investor conference, which included presentations from Daniel Mahony of Polar Capital and Martin Murphy of Syncona click below.